fda warning letters compounded semaglutide october 2025 Compound versions of GLP-1 drugs for weight loss halted by US FDA CDRH Warning Letters:

Emerging evidence points toward additional anti-inflammatory effects associated with semaglutide by suppressing IL-6 and TNF- - pro-inflammatory cytokines 30

These findings provide new insights into the pathogenesis of CM and suggest that microglial GLP-1R in the TNC may be a new target for the treatment of CM

Countries with significant sales include the United States, Canada, Mexico, the United Kingdom, Germany, France, Italy, Spain, Denmark, Sweden, Norway, China, Japan, India, South Korea, Australia, Thailand, Brazil, Argentina, South Africa, the United Arab Emirates, Kuwait, and Saudi Arabia [66]

Whilst diet soda does not interfere with Mounjaro's mechanism of action, focusing on hydrating beverages that contribute to overall nutritional goals may be more beneficial for optimising treatment outcomes and supporting long-term metabolic health

This information helps your provider identify factors affecting your response and develop an appropriate plan, whether that involves dose adjustment, additional testing for underlying conditions, referral to a dietitian or behavioral specialist, or consideration of alternative or adjunctive treatments